PMID- 33935503
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230920
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 14
DP  - 2021
TI  - A Novel Circular RNA circCSPP1 Promotes Liver Cancer Progression by Sponging 
      miR-1182.
PG  - 2829-2838
LID - 10.2147/OTT.S292320 [doi]
AB  - INTRODUCTION: Aberrant circular RNA (circRNA) expression has been extensively 
      discovered for its involvement in both the initiation and progression of various 
      cancers. Through screening circRNA profile, we identified a novel circRNA 
      has_circ_0001806, which is termed as circCSPP1 in liver cancer. In the present 
      study, we aim to investigate the role of circCSPP1 in the progression of liver 
      cancer. METHODS: Fluorescence in situ hybridization (FISH) was used to detect the 
      location of circCSPP1. Function studies including MTT, colony formation assay, 
      transwell assay and flow cytometry were carried out to detect the malignant 
      behaviour of circCSPP1 on liver cancer cells. Luciferase assay and RNA pull down 
      were used to detect the interaction between miR-1182 and circCSPP1 as well as 
      RAB15. Quantitative realtime (qPCR) and Western blot were performed to evaluate 
      the RNA and protein expression, respectively. RESULTS: CircCSPP1 knockdown 
      inhibited the proliferation, migration and invasion while promoted apoptosis of 
      liver cancer cells. Mechanically, we predicted and verified the target miR of 
      circCSPP1 which is miR-1182. miR-1182 was capable of reversing the effect of 
      circCSPP1 on liver cancer cells. Moreover, miR-1182 was found to also target 
      RAB15 to participate in the regulation of cell phenotype. DISCUSSION: Taken 
      together, circCSPP1 promoted progression of liver cancer cells via sponging 
      miR-1182 which may serve as a novel prognostic and therapeutic target for liver 
      cancer.
CI  - (c) 2021 Jia et al.
FAU - Jia, Nan
AU  - Jia N
AD  - Department of General Surgery, CangZhou General Hospital, CangZhou, Hebei, 
      061001, People's Republic of China.
FAU - Song, Zhe
AU  - Song Z
AD  - Department of General Surgery, CangZhou General Hospital, CangZhou, Hebei, 
      061001, People's Republic of China.
FAU - Chen, Baosheng
AU  - Chen B
AD  - Department of General Surgery, CangZhou General Hospital, CangZhou, Hebei, 
      061001, People's Republic of China.
FAU - Cheng, Jinsheng
AU  - Cheng J
AD  - Department of General Surgery, CangZhou General Hospital, CangZhou, Hebei, 
      061001, People's Republic of China.
FAU - Zhou, Wenyong
AU  - Zhou W
AD  - Department of General Surgery, CangZhou General Hospital, CangZhou, Hebei, 
      061001, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210423
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC8079351
OTO - NOTNLM
OT  - RAB15
OT  - circCSPP1
OT  - circRNA
OT  - liver cancer
OT  - miR-1182
COIS- The authors report no conflicts of interest in this work.
EDAT- 2021/05/04 06:00
MHDA- 2021/05/04 06:01
PMCR- 2021/04/23
CRDT- 2021/05/03 06:07
PHST- 2020/11/24 00:00 [received]
PHST- 2021/03/18 00:00 [accepted]
PHST- 2021/05/03 06:07 [entrez]
PHST- 2021/05/04 06:00 [pubmed]
PHST- 2021/05/04 06:01 [medline]
PHST- 2021/04/23 00:00 [pmc-release]
AID - 292320 [pii]
AID - 10.2147/OTT.S292320 [doi]
PST - epublish
SO  - Onco Targets Ther. 2021 Apr 23;14:2829-2838. doi: 10.2147/OTT.S292320. 
      eCollection 2021.